PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
24 Fevereiro 2022 - 6:00PM
Business Wire
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular diseases,
today announced that Chief Executive Officer Jonathan P. Mow will
participate in a panel discussion during Cowen’s 42nd Annual Health
Care Conference taking place virtually on Tuesday, March 8, 2022
from 12:50 pm – 1:50 pm ET.
Interested parties can access the live and archived webcasts of
the virtual session on the “Events and Presentations” page of the
“Investors” section of the company’s website at www.phasebio.com.
The webcast replay will be available for 90 days after the
conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular and
cardiopulmonary diseases. PhaseBio’s pipeline includes: bentracimab
(PB2452), a novel reversal agent for the antiplatelet therapy
ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor
agonist for the treatment of pulmonary arterial hypertension; and
PB6440, an oral agent for the treatment of resistant hypertension.
PhaseBio’s proprietary elastin-like polypeptide technology platform
enables the development of therapies with potential for
less-frequent dosing and improved pharmacokinetics, including
pemziviptadil, and drives both internal and partnership
drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more
information, please visit www.phasebio.com, and follow us on
Twitter @PhaseBio and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220224006067/en/
PhaseBio Investor Contact:
John Sharp Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
PhaseBio Media Contact: Will
Zasadny Canale Communications, Inc. (619) 961-8848
will.zasadny@canalecomm.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre PhaseBio Pharmaceuticals Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Phasebio Pharmaceuticals (MM)